Welcome to our dedicated page for P3 HEALTH PARTNERS SEC filings (Ticker: PIIIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
P3 Health Partners Inc. filings document the public-company reporting record for a population health management business and its Nasdaq-listed warrants exercisable for Class A common stock. Proxy statements cover annual meeting matters and corporate governance, while Form 8-K reports describe material agreements, amendments to debt instruments, unregistered equity securities, charter or bylaw matters and Nasdaq stockholders’ equity compliance topics.
The filing record also includes disclosures involving P3 Health Group, LLC and service arrangements under the company’s Care Enablement Model, including clinical, operational and data-driven support for primary care providers in Medicare Advantage networks.
P3 Health Partners Inc. director filed an amended insider trading report updating their share holdings after receiving a new equity grant. The director was granted 2,000 restricted stock units (RSUs) of Class A common stock on 08/06/2025 under the company’s 2021 Incentive Award Plan, at a price of $0 as this is an equity award. Each RSU represents one share of Class A common stock and will vest at the earlier of the company’s 2026 annual stockholder meeting or the one-year anniversary of the grant date.
The amendment corrects the number of shares beneficially owned to reflect the company’s 1-for-50 reverse stock split effective April 11, 2025, and to include certain indirectly owned securities. Following the correction, the director beneficially owns 6,331 Class A shares directly and 17,192 Class A shares indirectly through G&K Investment Holdings LLC, over which the director has voting and dispositive power.
P3 Health Partners Inc. director filed an amended insider trading report updating their share holdings after receiving a new equity grant. The director was granted 2,000 restricted stock units (RSUs) of Class A common stock on 08/06/2025 under the company’s 2021 Incentive Award Plan, at a price of $0 as this is an equity award. Each RSU represents one share of Class A common stock and will vest at the earlier of the company’s 2026 annual stockholder meeting or the one-year anniversary of the grant date.
The amendment corrects the number of shares beneficially owned to reflect the company’s 1-for-50 reverse stock split effective April 11, 2025, and to include certain indirectly owned securities. Following the correction, the director beneficially owns 6,331 Class A shares directly and 17,192 Class A shares indirectly through G&K Investment Holdings LLC, over which the director has voting and dispositive power.
P3 Health Partners Inc. director reports updated stock grant details. A director received 2,000 restricted stock units (RSUs) of Class A common stock on August 6, 2025 at a price of $0, reflecting a standard equity award for board service. Each RSU converts into one share of Class A common stock and vests at the earlier of the company’s 2026 annual stockholder meeting or one year after the grant date. After this grant, the director beneficially owns 6,331 Class A common shares directly.
This is an amended insider filing correcting the number of securities shown in Column 5 of Table I. The prior filing had inadvertently used the pre–reverse stock split amount instead of the post–split figure following the company’s 1-for-50 reverse stock split that became effective on April 11, 2025. The amendment is made solely to fix that post–split beneficial ownership number.
P3 Health Partners Inc. director reports updated stock grant details. A director received 2,000 restricted stock units (RSUs) of Class A common stock on August 6, 2025 at a price of $0, reflecting a standard equity award for board service. Each RSU converts into one share of Class A common stock and vests at the earlier of the company’s 2026 annual stockholder meeting or one year after the grant date. After this grant, the director beneficially owns 6,331 Class A common shares directly.
This is an amended insider filing correcting the number of securities shown in Column 5 of Table I. The prior filing had inadvertently used the pre–reverse stock split amount instead of the post–split figure following the company’s 1-for-50 reverse stock split that became effective on April 11, 2025. The amendment is made solely to fix that post–split beneficial ownership number.
P3 Health Partners Inc. director reported an updated insider holding following an equity award and corporate action. On 08/06/2025, the director received 4,000 restricted stock units (RSUs) of Class A common stock at a price of $0 under the company’s 2021 Incentive Award Plan. Each RSU converts into one Class A share and vests at the earlier of the company’s 2026 annual stockholder meeting or one year after the grant date.
The amended filing corrects the number of Class A shares beneficially owned after the company’s 1‑for‑50 reverse stock split effective April 11, 2025 and now includes securities held indirectly. Following the correction, the director is shown as beneficially owning 12,662 Class A shares directly and 8,520 Class A shares indirectly through AssetBlue Ventures, LLC, over which the director and Nasrin Thierer have voting and dispositive power.
P3 Health Partners Inc. director reported an updated insider holding following an equity award and corporate action. On 08/06/2025, the director received 4,000 restricted stock units (RSUs) of Class A common stock at a price of $0 under the company’s 2021 Incentive Award Plan. Each RSU converts into one Class A share and vests at the earlier of the company’s 2026 annual stockholder meeting or one year after the grant date.
The amended filing corrects the number of Class A shares beneficially owned after the company’s 1‑for‑50 reverse stock split effective April 11, 2025 and now includes securities held indirectly. Following the correction, the director is shown as beneficially owning 12,662 Class A shares directly and 8,520 Class A shares indirectly through AssetBlue Ventures, LLC, over which the director and Nasrin Thierer have voting and dispositive power.
P3 Health Partners Inc. director reported an equity grant and corrected prior share ownership figures. On 08/06/2025, the director received 2,000 restricted stock units (RSUs) of Class A common stock at a price of $0 under the company’s 2021 Incentive Award Plan. Each RSU represents one share of Class A common stock and will vest upon the earlier of the company’s 2026 annual stockholder meeting and the one-year anniversary of the grant date.
Following the update, the director is shown as beneficially owning 6,331 shares of Class A common stock directly. The amendment was filed to correct the number of securities beneficially owned after the company’s 1-for-50 reverse stock split, which became effective on April 11, 2025, and is limited to fixing that post-split share count.
P3 Health Partners Inc. director reported an equity grant and corrected prior share ownership figures. On 08/06/2025, the director received 2,000 restricted stock units (RSUs) of Class A common stock at a price of $0 under the company’s 2021 Incentive Award Plan. Each RSU represents one share of Class A common stock and will vest upon the earlier of the company’s 2026 annual stockholder meeting and the one-year anniversary of the grant date.
Following the update, the director is shown as beneficially owning 6,331 shares of Class A common stock directly. The amendment was filed to correct the number of securities beneficially owned after the company’s 1-for-50 reverse stock split, which became effective on April 11, 2025, and is limited to fixing that post-split share count.
P3 Health Partners disclosed an amendment to its Term Loan Agreement that revises payment timing, interest, and Paid-In-Kind (PIK) options while reaffirming existing loan obligations. The amendment extends the interest-only period to September 30, 2026 and pushes the loan maturity to December 31, 2027. Principal payments are changed to a fixed $5,000,000 on each payment date. The stated interest rate remains 12% through December 31, 2025 and then increases to 15% thereafter. The amendment replaces one PIK period with two: from closing through December 31, 2024 the borrower may pay 8% cash plus 4% PIK; from January 1, 2026 through December 31, 2027 the option is 12% cash plus 3% PIK. The amendment also updates board observation rights for lender representatives and includes standard conditions precedent for effectiveness.
P3 Health Partners Inc. reported continued operating losses and liquidity strain while scaling its Medicare Advantage-focused platform. The company recorded net losses of $43.7 million and $87.9 million for the three- and six-month periods ended June 30, 2025, respectively, and had $38.6 million of unrestricted cash as of June 30, 2025. A working capital deficit of $348.5 million and management's conclusion that substantial doubt exists about continuing as a going concern within one year were disclosed. The Company serves approximately 114,100 at-risk members through ~2,800 PCPs across 24 markets and relies on capitated per-member-per-month revenue. The filing describes related-party promissory financings (VGS 4 and VGS 5) carrying 19.5% annual interest with draw tranches and warrants, notes a 1-for-50 reverse stock split effective April 11, 2025, and discloses a DOJ civil investigative demand regarding broker arrangements.
P3 Health Partners Inc. director Gregory N. Kazarian was granted 2,000 restricted stock units (RSUs) on 08/06/2025, reported on a Form 4. Each RSU represents a right to receive one share of Class A common stock under the company’s 2021 Incentive Award Plan and the RSUs vest one year from the grant date. The award is reported with a $0 price as an equity grant and is coded as an acquisition.
After the grant Mr. Kazarian is reported to directly beneficially own 218,561 shares of Class A common stock. The Form 4 was signed by an attorney-in-fact on 08/08/2025. No derivative securities are reported in Table II of the filing.
Mary A. Tolan, a director of P3 Health Partners Inc., was granted 2,000 restricted stock units (RSUs) under the company 2021 Incentive Award Plan on 08/06/2025. Each RSU represents a right to receive one share of Class A common stock and the awards vest one year from the grant date. The grant was recorded with a reported price of $0. After the issuance, Ms. Tolan beneficially owns 218,561 shares of Class A common stock in a direct ownership form. The transaction was reported on a Form 4 as an acquisition by a reporting person who is a director.
P3 Health Partners reported that director Mark Thierer was granted 4,000 restricted stock units (RSUs) under the company’s 2021 Incentive Award Plan, with the award recorded on 08/06/2025. Each RSU represents the right to receive one share of Class A common stock and the RSUs vest in one year from the grant date, meaning the shares will be issued if the vesting conditions are met. The filing shows the RSUs were issued at no cash price and increased Thierer’s reported beneficial ownership to 437,121 shares, held directly. No derivative securities were reported in this filing.
P3 Health Partners Inc. director Gregory D. Wasson received a grant of 2,000 restricted stock units (RSUs) on 08/06/2025 reported on a Form 4. The RSUs were granted under the 2021 Incentive Award Plan and each RSU represents the right to receive one share of Class A common stock. The award carries a $0 price and vests one year from the grant date. Following the reported transaction, Mr. Wasson is shown as beneficially owning 218,561 shares directly. The filing was signed by an attorney-in-fact on 08/08/2025.